Super Vision Technology, Inc. announced National Medical Products Administration (NMPA) approval for its implantable ocular muscle neurostimulator, becoming the world’s first approved device for treating congenital horizontal nystagmus. The product, utilizing implantable extraocular muscle neuromuscular stimulation technology, is indicated for patients aged 8 years and above, offering a minimally invasive, controllable therapeutic option for this previously underserved ophthalmic condition.
Regulatory Milestone
Item
Detail
Agency
NMPA (China)
Approval Type
Marketing authorization (Class III medical device)
Product
Implantable ocular muscle neurostimulator
Developer
Super Vision Technology, Inc. (Beijing)
Indication
Improvement of symptoms in congenital horizontal nystagmus
Patient Population
Aged 8 years and above
Global Positioning
First-in-class – world’s first approved device for this indication
~1 in 1,000 to 1 in 6,500 births globally; China ~200,000–300,000 affected individuals with significant visual impairment burden
Unmet Need
No approved device therapies; current treatments symptomatic or invasive with limited efficacy
First-Mover Advantage
3–5 year regulatory lead in China; potential for FDA breakthrough device designation and EU MDR fast-track
Revenue Potential
Addressable market RMB 1–2 billion annually in China assuming 5–10% penetration; global licensing opportunity $500+ million
Platform Expandability
Technology applicable to other ocular motility disorders (strabismus, acquired nystagmus) and neuromuscular stimulation indications
Commercial Strategy: Tier-3 ophthalmology centers and pediatric specialty hospitals initial target; NRDL negotiation targeted for 2027 to expand access
Manufacturing: Domestic production facility in Beijing; capacity for 5,000–10,000 units annually at full scale
Forward‑Looking Statements This brief contains forward‑looking statements regarding commercial launch execution, physician adoption, and regulatory expansion for Super Vision’s ocular neurostimulator. Actual results may differ due to surgical training requirements, reimbursement negotiations, and competitive entry from alternative neuromodulation technologies.-Fineline Info & Tech
By Fineline Cube